Evogene Ltd. (EVGN) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 3, 2026, Evogene Ltd. (EVGN) trades at a price-to-earnings ratio of -0.3x, with a stock price of $0.83 and trailing twelve-month earnings per share of $-0.32.
Compared to the Healthcare sector median P/E of 23.4x, EVGN trades at a 101% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 190.3x.
Relative to the broader market, EVGN trades at a notable discount to the S&P 500 median P/E of 26.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our EVGN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
See EVGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EVGN Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare EVGN vs AGIO
See how EVGN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is EVGN stock overvalued or undervalued?
EVGN current P/E: -0.3x. 5-year average P/E: N/A. Percentile: N/A.
How does EVGN's valuation compare to peers?
Evogene Ltd. P/E of -0.3x compares to sector median of 23.4x. The discount suggests lower growth expectations or higher risk.
What is EVGN's PEG ratio?
EVGN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.